Aeterna Zentaris Inc., of Quebec City, said the independent data safety monitoring board completed an initial pre-specified interim futility analysis for the pivotal phase III ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin (AEZS-108) in women with advanced, recurrent or metastatic endometrial cancer and recommended that the trial continue as planned.